Tokyo, Jan 22, 2013 (JCN) - Teijin Limited announced today that it has signed a strategic partnership agreement with InCube Labs, a California-based life science research lab, to accelerate Teijin's healthcare business development. Teijin will invest in a company affiliated with InCube Labs.
By leveraging its extensive network and expertise, InCube Labs will help Teijin to define strategic growth opportunities for its healthcare business. Initiatives will include competitive evaluation of Teijin technologies, analysis of key market characteristics and regulations, and provision of information to help Teijin identify promising business partners and M&A opportunities.
Healthcare is one of the growth drivers in the Teijin group's medium- to long-term management vision. The group plans to integrate its materials and healthcare technologies to facilitate its expansion into fields including regenerative medicine and tissue repair, drug delivery systems and locomotive syndrome.
"To help us expand our healthcare business and create solutions for unmet medical needs, we sought a partner with deep understanding of the healthcare market, including technologies and business opportunities," said Kazuo Imose, Teijin Group Corporate Officer and General Manager of the New Business Incubation and Development Division. "InCube Labs' extensive knowledge and track record in healthcare innovation and company formation, including in the fields of medical instruments and materials, will be a tremendous asset as we pursue opportunities in the healthcare domain."
About InCube Labs
Based in Silicon Valley and San Antonio, InCube Labs is a life sciences research lab focused on developing medical breakthroughs that dramatically improve patient outcomes. Its multi-disciplinary approach integrates traditional device technologies such as electronics, software, mechanical engineering and material science, with innovations from the pharmaceutical industry, often involving protein chemistry, pharmacology and cell biology.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Teijin Develops Eco-friendly Wet-strong Printing Paper
(Mar 12, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping
(Feb 21, 2013)
|
|
|
Teijin Chemicals, SK Chemicals Form JV to Enter PPS Resin Business
(Feb 5, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business
(Jan 22, 2013)
|
|
|
Mitsubishi Outlander Uses Teijin's V-Lap Polyester Material
(Nov 28, 2012)
|
|
|
Teijin to Collaborate with China Chemical Fibers Association to Grow Chinese Market
(Mar 29, 2012)
|
|
|
Teijin Opens U.S. Composite Application Center
(Mar 26, 2012)
|
|
|
Teijin's MSABP System Used for Sewage Treatment Plant in China
(Mar 23, 2012)
|
|
|
ITOCHU to Deliver Sewage Facilities to Hunnan New Area, China
(Mar 15, 2012)
|
|
|
Teijin Thai Subsidiary Makes First Shipment after Flooding
(Feb 14, 2012)
|
|
|
|
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
|
|
Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign (Dec 20, 2012)
|
More Medical news...
|
|
